BioCentury
ARTICLE | Clinical News

Ablynx’s CD126 nanobody misses in Phase II for lupus

March 26, 2018 10:36 PM UTC

Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) said vobarilizumab (ALX-0061) missed the primary endpoint in the Phase II STEADY trial to treat systemic lupus erythematosus (SLE). The candidate is a nanobody against IL-6 receptor (CD126).

STEADY enrolled 312 patients with moderate to severe, active seropositive SLE to receive placebo or one of four dose regimens of subcutaneous vobarilizumab -- 75 mg every four weeks, 150 mg every four weeks, 150 mg every two weeks or 225 mg every two weeks...

BCIQ Company Profiles

Ablynx N.V.